Human Biome S.A.

Manufacture of pharmaceutical preparations

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2022-01-20
Share capital
160,774.20 PLN
Activity description

Human Biome is focused on research related to the gut microbiome and aims to create next-generation biotherapeutics for more effective disease treatment and health restoration. The company combines science and technology in its projects, which include a microbiota bank.

Registered address
ul. Starodworska 1, 80-137 Gdańsk, Poland
Phone
Social media
Electronic delivery address
AE:PL-69883-12578-GIFAE-15

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0

Filing timeliness

4 of 4 financial statements were filed late (the longest delay 83 days for 2025). All were audited by a statutory auditor.

  • 202506/10/2026
  • 202416/07/2025
  • 202301/08/2024
  • 202205/09/2023
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 59%
Sector · Manufacturing14,688 / 24,603
Top 60%
City · Gdańsk2,676 / 7,514
Top 36%
Voivodeship · Pomorskie7,799 / 20,081
Top 39%
Country · Poland115,741 / 297,566
Top 39%

Results vs industry

Revenue
This companyUSD 583.51kMedianUSD 913.43kAverageUSD 25.83m
Net profit
This companyUSD -1.88mMedianUSD 14.22kAverageUSD 2.77m
Operating costs
This companyUSD 2.44mMedianUSD 846.99kAverageUSD 21.38m
Assets
This companyUSD 3.80mMedianUSD 897.46kAverageUSD 31.54m

Offer

  • Microbiome medicines
  • Microbiome therapeutics
  • Microbiome research
  • Genomic analyses
  • Biobank services
  • Development of biological therapies

Websites

  • human-biome.comHuman Biome | Next-Generation Microbiome Therapeutics
    WordPress 7.1Nginx

Public procurement

20 tenders recorded as contractor: 10 national ($726,913) and 10 EU ($291,158).

SubjectAmount
Stool processing service for intestinal microbiota transfer
–
Successive supply of pharmaceutical products to Wojewódzki Szpital Zespolony w Kaliszu
$14,317
Supply of medicines, foodstuffs for special medical purposes and pharmaceutical ingredients – 27 lots.
$35,367

Authorized Representatives

Jarosław Józef Biliński age 40 – President of the Management Board

Manner of representation

In the case of a one-person management board, the sole member of the management board is entitled to make declarations of will concerning the company’s rights and obligations on behalf of the company. In the case of the appointment of a multi-member management board, each member of the management board is entitled to make declarations of will concerning the company’s rights and obligations on behalf of the company independently.

Supervisory board

Robert Aleksandrowicz age 60 – Supervisory Board Member
Stefan Chabiera age 46 – Supervisory Board Member
Grzegorz Szostek age 38 – Supervisory Board Member
Łukasz Jankowski age 39 – Supervisory Board Member
Wojciech Konarski age 40 – Supervisory Board Member

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2020-03-20.

Debt

No entries in the National Debtors Register (KRZ).

MSiG notices

Publication dateEvent
Dec 1, 2022Transformation registered

Public aid

4 public aid cases recorded, with a total value of $4,743,832.

PurposeGross amount
De minimis aid (in accordance with Commission Regulation 2023/2831)
–
Aid for research and development projects: industrial research
–
Aid for research and development projects: experimental development
–

European Funds

ProjectEU co-financing
Development of an advanced FMT formulation – an ecobiotic containing concentrated and preserved human gut microbiota with an extracellular matrix for increased stability, viability and efficacy in the treatment of CDI infections
$6.5M
Preparation of an application for a Eurogrant planned under the EIC pre-accelerator - Widening programme
$17,431
Preparation of application documentation for the project provisionally titled: “Development of a next-generation biotherapeutic based on components of the gut microbiota to combat antimicrobial resistance”, planned for implementation under the EIC Pathfinder Open programme
$5,215

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Scope Fluidics S.A.
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Nanogroup S.A.
Bioresearch Group sp. z o.o.
Simbec-Orion (Pol) sp. z o.o.
Precisionlife Poland sp. z o.o.
Camino Science sp. z o.o.
Prolab sp. z o.o. + limited partnership
Vaxican sp. z o.o.
Medicofarma Biotech S.A.

Change history

DateEvent
2026-08-26Share capital increase
2026-03-26Share capital increase
2025-07-17Name change
2025-02-04Share capital increase
2023-09-21Share capital increase

FAQ

Last updated: 2026-10-06